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Despite the human 5-HT5A receptor being cloned in 1994, the biological function of this receptor has not
been extensively characterized due to a lack of speciﬁc ligands. We recently reported that the selective 5-
HT5A receptor antagonist ASP5736 ameliorated cognitive impairment in several animal models of
schizophrenia. Given that areas of the brain with high levels of 5-HT5A receptor expression, such as the
hippocampus and cerebral cortex, have important functions in cognition and memory, we evaluated the
chemically diverse, potent and brain-penetrating 5-HT5A receptor antagonists ASP5736, AS2030680, and
AS2674723 in rodent models of cognitive dysfunction associated with dementia. Each of these com-
pounds exhibited a high afﬁnity for recombinant 5-HT5A receptors that was comparable to that of the
non-selective ligand of this receptor, lysergic acid diethylamide (LSD). Although each compound had a
low afﬁnity for other receptors, 5-HT5A was the only receptor for which all three compounds had a high
afﬁnity. Each of the three compounds ameliorated scopolamine-induced working memory deﬁcit in mice
and improved reference memory impairment in aged rats at similar doses. Further, ASP5736 decreased
the binding of LSD to 5-HT5A receptors in the olfactory bulb of rats in a dose-dependent manner and
occupied 15%e50% of brain 5-HT5A receptors at behaviorally effective doses. These results indicate that
the 5-HT5A receptor is involved in learning and memory and that treatment with 5-HT5A receptor an-
tagonists might be broadly effective for cognitive impairment associated with not only schizophrenia but
also dementia.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The 5-HT5A receptor is a G-protein-coupled, seven-
transmembrane receptor among 5-HT receptors. Despite being
cloned in 1994 (1), a lack of speciﬁc ligands has meant that the
function of the human 5-HT5A receptor has only been recently
characterized.
Findings from 5-HT5A receptor mRNA localization (1,2) and
immunolabeling (3) studies have revealed widespread expression
in the CNS, including the cerebral cortex, hippocampus, nucleus
accumbens, amygdala, and hypothalamus, with limited expression: þ81 29 856 2515.
. Yamazaki).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).in peripheral tissues. These patterns of expression indicate poten-
tial functions of the receptor. In addition, the increased exploratory
behavior exhibited by 5-HT5A receptor KOmice compared to that by
wild-type mice (4) and widespread localization pattern suggest
that the 5-HT5A receptor is involved inmood, affective disorder, and
cognitive function. Gene-association studies suggested that the 5-
HT5A receptor might also play a role in schizophrenia (5,6). We
recently demonstrated that the novel 5-HT5A receptor antagonist
ASP5736 ameliorated positive symptoms and cognitive impairment
in animal models of schizophrenia (7).
Here, we investigated the relationship between the 5-HT5A re-
ceptor and cognitive function using three 5-HT5A receptor antag-
onists with different scaffolds, as follows: ASP5736 (N-
(diaminomethylene)-1-(3,5-diﬂuoropyridin-4-yl)-4-ﬂuoroisoquin-
oline-7-carboxamide (2E)-but-2-enedioate), AS2030680 (N-(dia-
minomethylene)-4-(2,4,6-triﬂuorophenyl)-2H-chromene-6-nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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methylene)-5-ﬂuoro-8-(2,4,6-triﬂuorophenyl)-3,4-dihydroisoqu
inoline-2(1H)-carboxamide (2E)-but-2-enedioate). We also con-
ducted a 5-HT5A receptor occupancy study around the effective
doses of ASP5736 in ex vivo animal models.
2. Materials and methods
2.1. Drugs and treatment
ASP5736, AS2030680 and AS2674723 (Fig. 1) were synthesized
at Astellas Pharma Inc. (Tsukuba, Japan). ()-Scopolamine hydro-
bromide trihydrate (scopolamine) was purchased from Sigma
Aldrich (St. Louis, MO, USA). ASP5736, AS2030680 and AS2674723
were suspended in 0.5% (W/V) methyl cellulose (MC), and scopol-
amine was dissolved in saline. Compounds were administered at a
volume of 10 mL/kg in mice and 1 mL/kg in rats. Doses were cor-
rected for salt content.
2.2. In vitro binding assay to human, mouse and rat 5-HT5A
receptors
2.2.1. Acquisition of cell membrane expressing 5-HT5A receptors
An open reading frame (ORF) of the human 5-HT5A receptor
(GenBank AF498985) was cloned from a human whole brain cDNA
library and inserted into a pCR2.1 vector (Life Technologies, Carls-
bad, CA, USA). Escherichia coli containing the plasmid was then
mass cultured. The full-length cDNA sequence of the human 5-HT5A
receptor was then analyzed and inserted into a pCDNA3.1 recom-
binant expression vector (Life Technologies). Human embryonic
kidney (HEK) 293 cells (American Type Culture Collection, Mana-
ssas, VA, USA) were seeded, and the aforementioned expression
plasmid (1 mg) and lipofectamine 2000 (Life Technologies; 2 mL)Fig. 1. Structures of ASP5736, AS2030680 and AS2674723.were added to induce the gene. Geneticin (G418 sulfate 500 mg/mL;
Kanto Chemical Co., Inc., Tokyo, Japan) was used as a drug-
resistance marker to screen for cells expressing the human 5-
HT5A receptor.
An ORF of the murine 5-HT5A receptor (GenBank Z18278) was
subcloned from a mouse brain cDNA library into a pGEM-T-Easy
vector (Promega KK, Tokyo, Japan). After sequence analysis, the
murine 5-HT5A receptor full-length cDNA sequence was inserted
into a pCDNA3.1 recombinant expression vector (Life Technologies),
and the plasmid was transformed to E. coli and cultured. An ORF of
the rat 5-HT5A receptor (GenBank L10072) was subcloned from rat
genomic DNA into a pCR2.1 vector (Life Technologies). After
sequence analysis, the full-length cDNA sequence of the rat 5-HT5A
receptor was inserted into a pEF-BOS-dhfr recombinant expression
vector (gift from Dr. S. Nagata, Osaka Bioscience Institute, Japan),
and the plasmid was transformed to E. coli and cultured.
2.2.2. Afﬁnities for human, mouse and rat 5-HT5A receptors
The 5-HT analog of 5-carboxamidetryptamine (5-CT) was pur-
chased from Tocris Biosciences (Bristol, UK), while [3H]-5-CT was
purchased from PerkinElmer (Waltham, MA, USA). Cell membranes
(25 mg of protein), [3H]-5-CT (1.5 nM at ﬁnal concentration), and
test compounds (0.03e30 nM at ﬁnal concentration) were seeded
in 96-well plates and incubated for 60 min at 37 C in incubation
buffer (TriseHCl 50 mM pH 7.4, MgSO4 10 mM, EDTA 0.5 mM). The
reaction was terminated via rapid ﬁltration through 96-well GF/C
ﬁlter plates (PerkinElmer) pre-soaked with 0.3% polyethyleneimine
for 30 min. Filter plates were washed 5 times with 50 mM TriseHCl
at pH 7.4 and dried. Liquid scintillant (30 mL; MicroScint™-20,
PerkinElmer) was placed on ﬁlters, and radioactivity was measured
using a TopCount (PerkinElmer). Non-speciﬁc binding was deter-
mined with 1.5 mM of 5-CT.
Values of the apparent equilibrium dissociation constant of in-
hibitors (Ki) were calculated using SAS version 8.2 (SAS Institute
Inc., Cary, NC, USA). Mean and standard error of the mean (SEM)
were obtained from three independent experiments.
Inhibition constants (Ki values) were calculated from IC50 values
using the Cheng-Prusoff equation, as follows:
Ki ¼ IC50/(1 þ Concentration of the ligand added/Kd)
The Kd value of [3H]-5-CT was determined by non-linear
regression analysis.
2.3. Afﬁnities for multiple receptors, ion channels and transporters
To determine the binding afﬁnities for a wide range of receptors,
transporters and ion channels, initial receptor binding screens (62
assays) were conducted with duplicate samples of ASP5736 (1 mM),
AS2030680 (1 mM), and AS2674723 (300 nM) at Sekisui Medical Inc.
(Tokyo, Japan) using proprietary assay formats.
2.4. Animals
Animals were housed in groups of 10 (mice), 5 (young rats) or 3
(aged rats) in temperature- and humidity-set rooms (23 ± 2 C and
55% ± 10%) under a 12-h light/dark cycle with water and laboratory
chow supplied ad libitum. Animals (including aged rats) were
experimentally naive and only used once. In vivo experimental
procedures were performed during the light cycle. Animal experi-
mental procedures were approved by the Institutional Animal Care
and Use Committee of Astellas Pharma Inc. Further, the Astellas
Pharma Inc. Tsukuba Research Center was previously awarded
Accreditation Status by the AAALAC International. Every effort was
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and distress.
2.5. Drug concentrations in biological samples
Seven- to nine-week-old male mice (Japan SLC, Inc., Hama-
matsu, Japan) and 24- to 26-month-old male rats (Charles River
Laboratories Japan, Inc.) that had been freely feeding were used. In
the ﬁrst examination, animals received an oral (p.o.) administration
of compounds suspended in 0.5% MC and were kept in rearing
cages. Animals were sacriﬁced under isoﬂurane anesthesia, and
whole blood samples and cerebrum were taken at 0.5, 1, and 2 h
post-dose.
Given that these compounds were well absorbed and reached
the cerebrum less than 1 h post-administration, animals receiving
subsequent oral administrations of compounds were sacriﬁced
under isoﬂurane anesthesia at 1 h post-dose. Whole blood samples
were then taken using a syringe containing heparin sodium. After
collection of whole blood, the cerebrum was removed from each
animal. Whole blood samples were centrifuged to separate plasma.
Plasma and cerebrum were stored at 20 C until assay.
For analysis, 25 mL of plasma was mixed with 25 mL of 50%
acetonitrile and 200 mL of acetonitrile containing internal standard
(IS; ﬁnal: 20 ng/mL diazepam). The mixture was subjected to
centrifugation at 2150 g for 10min, and the resulting supernatant
was injected into a LC-MS/MS system. This system comprised the
Prominence HPLC system (Shimadzu, Kyoto, Japan) with an XTerra
MS C18 column (4.6  50 mm, 5 mm particle size; Waters, Milford,
MA, USA) and an API4000 LC/MS/MS System (AB SCIEX, Framing-
ham, MA, USA). Data were processed using Analyst software (AB
SCIEX, Ontario, Canada), and the concentration of each compound
was calculated using internal standards.
2.6. Scopolamine-induced spontaneous alternation deﬁcit in mice
during Y-maze test
Spatial working memory performance was assessed by
recording spontaneous alternation behavior in a Y-maze as previ-
ously described (8,9). Male ddY mice (5e6 weeks old; Japan SLC,
Inc.) were used. The maze was made of gray polyvinyl chloride,
with arms 40 cm long, 13 cm high, and 3 cmwide at the bottom and
10 cm at the top that converged at equal angles. Thirty minutes
after oral administration of test compounds, each animal received
an intraperitoneal administration of 0.5 mg/kg of scopolamine.
Twenty minutes after administration of scopolamine, each mouse
was placed at the end of one arm and allowed to explore the
apparatus freely for 8 min. The sequence and number of all arm
entries were recorded for each animal throughout this period.
Alternation was deﬁned as entries into all three arms on consecu-
tive occasions. The percentage of alternation was calculated using
the following formula:
Alternation rate (%) ¼ 100  Number of alternations/(Number of
total arm entries  2)
2.7. Morris water maze test for aged rats
Young male Fischer 344 rats (aged 9 weeks) and aged rats (aged
25 months; Charles River Laboratories Japan, Inc.) were used. All
animals were given food and water ad libitum. The apparatus and
experimental procedures were similar to those previously
described (10e12). Brieﬂy, all animals were trained in the Morris
water maze with two trials per day. The rat water maze apparatus(Neuroscience Co., Tokyo, Japan) consisted of a circular pool
(150 cm in diameter) that was ﬁlled with water to a depth of 30 cm
at 22 C. An invisible platform (12 cm in diameter), made of clear
plastic and supported by a base resting on the bottom of the pool,
was placed 1.3e1.5 cm below thewater surface. At the start of a trial
the rat was placed at one of the two cardinal starting points located
farthest from the platform (North or East) in a semi-random order.
The same location was not used on two consecutive days. When
rats found the platform, they were allowed to remain on it for 15 s.
In cases where the rats did not ﬁnd the platform within 90 s, they
were removed from the water and then placed on the platform for
15 s. The second daily trial began approximately 4 min after the
conclusion of the ﬁrst with the starting location of the second trial
being a random choice of the two remaining locations (South or
West).
Animals were trained in the water maze for 4 consecutive days.
Data were collected using an automated on-line video device
designed to track the object with the highest contrast in the ﬁeld of
vision, which was always the white rat on the black background.
Escape latency (the time to ﬁnd the platform), escape distance and
velocity (distance/latency) were recorded for each trial with a video
tracking system (EthoVision ver. 3.0 by Noldus, Netherlands). Mean
daily latency and daily velocity for ﬁnding the hidden platform
were obtained from the two daily trials. The cumulative latencies
for 4-day training were also calculated from sum of daily latencies
in each treatment group. Further, the average velocity was calcu-
lated from the average daily velocity for 4 days.
ASP5736, AS2030680, and AS2674723 were orally administered
1 h before the ﬁrst trial for 4 consecutive days.
2.8. Ex vivo receptor occupancy study for rat 5-HT5A receptor
ASP5736 or vehicle was orally administered to 8-week-old male
Wistar rats (Charles River Japan) at a dose of 0.001, 0.01, 0.1, 1, or
10 mg/kg as free base. Rats were sacriﬁced 1 h after administration,
and olfactory bulbs were immediately collected and stored with an
OCT compound (Sakura Finetek, Tokyo, Japan) at 80 C. Olfactory
bulbs were cut into 30-mm coronal sections using a cryostat and
then placed on slides. Sections were pre-treated with 600 nM of
spiperone (SigmaeAldrich) and clozapine (SigmaeAldrich) with or
without 500 nM 5-HT in 50 mM TriseHCl buffer (pH 7.4) for 15 min
at room temperature (RT). Sections were then treated with 500 pM
[125I]-LSD (PerkinElmer) for 15 min at RT. After washing with
50 mM TriseHCl buffer (pH 7.4) for 10 min a total of three times at
RT, sections were exposed to imaging plates (Fuji Film, Tokyo,
Japan) and then analyzed with a FLA7000 (GE Healthcare, Buck-
inghamshire, UK) and appropriate software (GE Healthcare). [125I]-
LSD binding in 500 nM 5-HT-treated sections was regarded as non-
speciﬁc binding (NSB) and was calculated using the following
equation:
LSD binding (%) ¼ 100  (binding in ASP5736 treatment  NSB)
/(binding in vehicle treatment  NSB)
2.9. Statistical analysis
For behavioral studies, multiple groups were compared using
Dunnett's multiple comparison test. Statistical analysis of control
(vehicle and saline) group vs. vehicle and scopolamine group, or of
young group (vehicle) vs. aged group (vehicle) was conducted using
unpaired Student's t-test. In the case of the cumulative latencies for
4-day training of the water maze, Student's t-test and Dunnett's
multiple comparison test were used to compare two groups and
Table 2
Afﬁnities of compounds for 5-HT receptor subtypes.
Molecule ASP5736 AS2030680 AS2674723
5-HT1A (human) IC50 >1000 nM Ki ¼ 20.7 nM Ki ¼ 83.8 nM
5-HT2A (human) IC50 >1000 nM >300 nM >300 nM
5-HT2B (human) IC50 >1000 nM Ki ¼ 22.0 nM >300 nM
5-HT2C (human) IC50 Ki ¼ 286.8 nM >300 nM >300 nM
5-HT3 (human) IC50 >1000 nM >100 nM >300 nM
5-HT4 (guinea pig) IC50 >1000 nM >100 nM >300 nM
5-HT6 (human) IC50 >1000 nM Ki ¼ 39.3 nM >300 nM
5-HT7 (human) IC50 Ki ¼ 122.9 nM Ki ¼ 10.3 nM Ki ¼ 7.3 nM
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statistically signiﬁcant.
3. Results
3.1. Afﬁnities of compounds for cloned 5-HT5A receptors from
different species and other receptors
5-CT has a high afﬁnity for cloned 5-HT5A receptors from
different species, e.g. humans, rats and mice. The pKi values of 5-CT
for these cloned receptors were all approximately 8.0 (13). The Ki
values of each compound were then evaluated from [3H]-5-CT
binding experiments for recombinant human, rat, and mouse 5-
HT5A receptors (Table 1). However, while all three compounds
exhibited a similar, high afﬁnity for the 5-HT5A receptors of each
species, they also exhibited low afﬁnities for other 5-HT receptor
subtypes, such as the 5-HT2B and 5-HT7 receptors.
ASP5736 exhibited an afﬁnity for the 5-HT7 receptor, but at a
level 30-fold lower than that for the 5-HT5A receptor. Although
AS2030680 exhibited slightly higher afﬁnities for the 5-HT1A, 5-
HT2B, and 5-HT7 receptors than the other two compounds, these
were approximately 17-fold lower than that for the 5-HT5A recep-
tor. Similar to the other two compounds, AS2674723 also had af-
ﬁnity for the 5-HT7 receptor but still maintained 10-fold greater
selectivity for 5-HT5A receptor (Table 2).
We then evaluated selectivity for the 5-HT5A receptor over a
wide range of other receptors, transporters, and channels using a
commercial screening package (Sekisui Medical Inc. (Tokyo, Japan))
(Tables 2 and 3). AS2674723 had moderate afﬁnity for the rat a2-
adrenergic receptor and AS2030680 a high afﬁnity. Compared to
that for the rat 5-HT5A receptor, the afﬁnity for this receptor was
approximately 10-fold lower for AS2674723 and approximately 2-
fold lower for AS2030680. In contrast, ASP5736 had no afﬁnity
for this receptor. The three compounds share a high afﬁnity for the
5-HT5A receptor.
3.2. Concentration of drugs in plasma and brain in mice and aged
rats
Table 4 shows the concentrations of ASP5736, AS2030680 and
AS2674723 in plasma and brain in mice and aged rats 1 h after oral
administration. These results suggest that all three compounds
were well absorbed after oral administration and reached the brain
within 1 h in both mice and aged rats (Table 4).
3.3. Effects of compounds on spontaneous alternation deﬁcits
caused by scopolamine in the mouse Y-maze test
Administration of scopolamine induced a marked decrease in
the alternation rate in the Y-maze test (P < 0.01, by Student's t-test),
as reported previously (14). ASP5736, AS2030680, and AS2674723
signiﬁcantly restored the scopolamine-induced decrease in alter-
nation rate, and statistical analysis revealed a signiﬁcant effect of anTable 1
Afﬁnities of compounds for cloned 5-HT5A receptors from different species.
Compound Ki (nM)
Human Rat Mouse
ASP5736 3.6 ± 0.66 1.7 ± 0.42 4.4 ± 0.88
AS2030680 0.58 ± 0.17 1.1 ± 0.40 2.6 ± 0.28
AS2674723 0.75 ± 0.03 0.67 ± 0.14 1.9 ± 0.28
Ki values from [3H]5-CT binding experiments. Data are themean ± SEM from at least
three separate experiments, each performed in duplicate.oral (p.o.) dose of ASP5736 at 0.001e0.003mg/kg and of AS2674723
at 0.01e0.03mg/kg (Fig. 2A and E). AS2030680 exerted a signiﬁcant
effect at doses from 0.003 to 0.03 mg/kg, p.o. (Fig. 2C). The number
of arm entries was not affected by any of the compounds (Fig. 2B, D
and F).
3.4. Effects of compounds on reference memory deﬁcit in aged rats
Fig. 3 shows the effects of the three 5-HT5A antagonists on
spatial learning deﬁcits in aged rats during the Morris water maze
test. In young control rats, the daily latency in ﬁnding the platform
progressively declined during the training period of 4 consecutive
days (Fig. 3A, C and E). In all cases, the cumulative latency in ﬁnding
the platform was signiﬁcantly longer in aged rats compared to
young rats, as shown in Fig. 3B, D and F (P < 0.01, Student's t-test).
Treatment with ASP5736 signiﬁcantly ameliorated the longer cu-
mulative latency of aged rats at doses of 0.001e0.03 mg/kg, as
shown in Fig. 3B (P < 0.01; Dunnett's multiple comparison test).
AS2030680 and AS2674723 also signiﬁcantly reduced the cumu-
lative latency of aged rats at doses of 0.03 and 0.1 mg/kg (Fig. 3D)
and 0.01 and 0.03 mg/kg, (Fig. 3F), respectively. None of the com-
pounds affected the average velocity of aged rats.
3.5. Ex vivo receptor occupancy study for 5-HT5A receptors
Only the occupancy rate of ASP5736 for the 5-HT5A receptor was
examined, as the binding of LSD to the 5-HT1A, 5-HT2A, 5-HT2C, 5-
HT6, 5-HT7, D2, D3, and D4 receptors was masked by spiperone
and clozapine. ASP5736 exhibited dose-dependent receptor occu-
pancy with an ED50 value of 0.033 mg/kg (Fig. 4), which demon-
strates that ASP5736 binds to the 5-HT5A receptor.
4. Discussion
Widespread expression of 5-HT5A receptors in the brains of
mice, rats and humans has been reported in mRNA localization and
immunohistochemical studies (1e3,15e17). These patterns of tis-
sue localization suggest the involvement of this receptor in a pro-
portion of psychiatric disorders. We recently observed that a novel
5-HT5A antagonist ligand attenuated cognitive dysfunction in
several animal models of schizophrenia (7). In the present study,
we evaluated the effects of novel 5-HT5A antagonists on cognitive
dysfunction associated with dementia such as the cholinergic
deﬁcit and aged rat models.
We synthesized novel 5-HT5A antagonists with various scaffolds.
Although each of the three compounds exhibited a high afﬁnity for
human, mouse, and rat 5-HT5A receptors, some also exhibited af-
ﬁnity for other 5-HT receptor subtypes, such as 5-HT1A, 5-HT2B, 5-
HT2C, 5-HT6, and 5-HT7 receptors. ASP5736 exhibited an afﬁnity
for the 5-HT7 receptor, and AS2030680 exhibited slightly higher
afﬁnities for the 5-HT1A, 5-HT2B, and 5-HT7 receptors than the other
two compounds. AS2674723 also had afﬁnity for the 5-HT7
Table 3
Afﬁnities of compounds for multiple receptors, ion channels and transporters.
Inhibition (%)
ASP5736
1000 nM
AS2030680
1000 nM
AS2674723
300 nM
Adenosine A1 (Rat) 3.18 3.16 0.25
a1-Adrenergic (Non-selective) (Rat) 3.52 11.15 2.90
a2-Adrenergic (Non-selective) (Rat) 48.26 100.00 76.72
b-Adrenergic (Non-selective) (Rat) 36.41 32.84 29.27
Angiotensin AT1 (Human) 7.04 0.00 2.95
Angiotensin AT2 (Mouse) 16.62 0.68 8.89
Bradykinin B2 (Human) 0.00 0.00 7.09
Ca Channel (Type L, Dihydropyridine)
(Rat)
0.98 2.39 5.26
Ca Channel (Type N) (Rat) 0.00 0.29 0.28
CCK A (Human) 4.82 0.00 0.00
CCK B (Human) 0.00 4.52 2.52
CRF1 (Human) 3.02 0.00 0.00
Dopamine D1 (Rat) 0.50 2.88 3.16
Dopamine D2 Short (Human) 5.81 0.96 5.44
Dopamine Transporter (Human) 5.77 43.64 7.43
Estrogen (Rat) 1.09 3.29 0.42
Endothelin ETA (Human) 21.46 2.20 0.60
Endothelin ETB (Human) 14.66 3.65 4.75
GABA A (Agonist Site) (Rat) 0.00 19.17 9.00
GABA A (BZ Central) (Rat) 3.86 2.17 0.00
GABA B (Rat) 0.00 0.41 7.06
Glutamate (AMPA) (Rat) 0.00 0.00 0.00
Glutamate (Kainate) (Rat) 2.21 0.00 3.34
Glutamate (NMDA Agonist Site) (Rat) 2.17 0.00 0.00
Glutamate (NMDA Glycine Site) (Rat) 0.00 2.40 8.59
Glycine (Strychnine Sensitive) (Rat) 0.00 14.48 0.00
Histamine H1 (Central) (Guinea pig) 2.98 17.68 7.24
Histamine H2 (Rat) 8.93 3.43 2.57
Histamine H3 (Rat) 2.93 28.41 3.05
K Channel KATP (Rat) 0.85 2.24 0.51
K Channel SkCa (Rat) 8.65 3.13 9.67
Leukotriene B4 (Guinea pig) 1.41 2.51 3.62
Leukotriene D4 (Guinea pig) 0.34 3.95 15.03
Melatonin MT1 (Human) 2.31 9.58 5.14
Muscarinic (Non-selective) (Rat) 1.41 0.16 12.54
Muscarinic M1 (Human) 0.00 21.22 27.40
Muscarinic M2 (Human) 1.48 3.48 31.54
Na Channel Site 2 (Rat) 23.82 71.03 40.85
Neurokinin NK1 (Human) 0.00 0.00 12.81
Neurokinin NK2 (Human) 0.00 0.00 0.09
Neurokinin NK3 (Human) 5.13 0.38 3.41
Norepinephrine Transporter (Human) 18.56 48.08 5.96
Nicotinic Ni (Rat) 16.80 1.34 5.48
Opiate (Non-selective) (Rat) 5.80 41.69 0.63
Opiate m (Human) 4.51 30.95 7.77
Oxytocin (Rat) 0.00 3.70 11.87
PAF (Rabbit) 0.36 0.00 5.33
Serotonin Transporter (Human) 6.41 5.46 7.05
Sigma (Non-selective) (Guinea pig) 10.20 13.39 16.30
Testosterone (Human) 0.00 4.48 0.17
Vasopressin V1 (Rat) 4.46 1.29 1.70
VIP 1 (Human) 1.21 17.01 15.22
Acetylcholinesterase (Human) 4.50 5.27 (Eel) 3.24
MAO-A (Rat) 1.70 0.00 0.00
MAO-B (Rat) 0.00 4.99 19.12
Data are expressed as mean of duplicate samples.
Inhibition rate calculated from “100  reaction ratio”.
Reaction ratio: [(B  N)/(B0  N)]  100 (%)
B: Radioactivity or ﬂuorescence intensity in the tube for calculation of inhibition rate
(individual value).
B0: Radioactivity or ﬂuorescence intensity of the tube for calculation of total reaction
(mean value).
N: Radioactivity or ﬂuorescence intensity of the tube for calculation of non-speciﬁc
reaction (mean value).
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HT receptor subtypes, they still maintained more than 10-fold
greater selectivity for 5-HT5A receptor (Table 2). Two of the three
compounds showed a slightly high afﬁnity for the rat a2-adrenergicreceptor. To evaluate the effect of compounds via a2-adrenergic
receptor on cognition in behavioral tests, we evaluated the effects
of the a2-adrenergic receptor antagonist yohimbine on
scopolamine-induced spontaneous alternation deﬁcit in mice
during a Y-maze test. Yohimbine had no effect on scopolamine-
induced cognitive deﬁcit or number of arm entries (data not
shown). In rats, none of the three compounds had any effect on
blood pressure, even at doses 100-fold higher than the behaviorally
effective dose. The results of the present study indicate only minor
involvement of a2-adrenergic receptor, if any, in behavioral tests.
To evaluate the effects of the 5-HT5A antagonists in behavioral
tests, we ﬁrst measured the concentration of unchanged com-
pounds in plasma and brain after oral administration. All three
compounds were well absorbed after oral administration and
reached the brain within 1 h in mice and aged rats.
Following the cholinergic hypothesis of Alzheimer's disease
(AD), induction of learning deﬁcits by the anticholinergic agent
scopolamine is frequently used to create animal models of cogni-
tive impairment in dementia (18). In the Y-maze, alternation
behavior requires mice to remember which arm has been visited
most recently. Therefore, alternations in behavior might be regar-
ded as a measure involving spatial working memory (14). In the
present study, the oral administration of 5-HT5A antagonists
ameliorated the spontaneous alternation deﬁcits (cognitive
impairment) caused by scopolamine in the Y-maze test with no
inﬂuence on the number of arm entries. 5-HT5A antagonists have
been reported to increase acetylcholine levels in the medial pre-
frontal cortex (mPFC) (19). Although the mechanism by which 5-
HT5A antagonists enhance mPFC ACh release is unknown, 5-HT5A
antagonists might ameliorate the cognitive deﬁcit by increasing the
level of ACh in the mPFC.
Given that aged rats exhibit cognitive impairment (20), they are
often used as animal models of cognitive impairment in AD. In the
present study, the daily and cumulative latencies of aged rats in
ﬁnding a platformwere longer than those of young rats, suggesting
age-related reference memory impairment. From the data of more
than 600 aged rats, we observed only minor improvement in their
performance over the repeated testing days. In addition, we
conﬁrmed that three compounds with different scaffolds amelio-
rated memory impairment of aged rats in a water maze task.
However, these compounds failed to completely recover the deﬁ-
cits of aged rats in this maze. In contrast, we previously reported (9)
that the acetylcholinesterase inhibitor donepezil did not affect the
daily or cumulative latency in aged rats in a water maze task.
Donepezil is not beneﬁcial for all AD patients, and therefore a 5-
HT5A receptor antagonist might be effective for this subset of re-
fractory AD patients.
The lack of efﬁcacy of donepezil in our water maze task suggests
that an increase in levels of acetylcholine alone is insufﬁcient for
cognitive improvement in aged rats. Substantial evidence has
implicated changes in PFC monoamine signaling in age-related
working memory impairment (21e23). In fact, the dopamine
(DA) releaser methamphetamine improved the impaired passive
avoidance response in aged rats (24). Similar doseeresponse re-
lationships have been reported to facilitate the effects of amphet-
amine and apomorphine on passive avoidance learning (25,26). In a
recent immunohistochemistry study, we observed that 5-HT5A re-
ceptors are co-expressed on DA neurons (tyrosine hydroxylase-
positive) in the ventral tegmental area (VTA) (7). We therefore
hypothesize that 5-HT5A receptor antagonists block inhibitory 5-
HT5A receptors on DA neurons in the VTA, which enables projec-
tion to the mPFC and thereby improves cognitive impairment by
activating DA neurons in the mPFC. These results will be presented
in future publications. There have been reports of an inverted-U
relationship between prefrontal DA transmission and cortical
Table 4
Plasma and brain concentrations of ASP5736, AS2030680, AS2674723 in mice and aged rats.
Compound Mice Aged rats
Dose (mg/kg) Plasma (ng/mL) Brain (ng/g brain) Kp brain Dose (mg/kg) Plasma (ng/mL) Brain (ng/g brain) Kp brain
ASP5736 0.03 9.5 ± 1.0 1.5 ± 0.8 0.15 0.03 7.1 ± 1.5 0.7 ± 0.09 0.10
AS2030680 0.1 3.0 ± 0.3 1.6 ± 0.1 0.53 0.1 0.4 ± 0.2 0.1 ± 0.07 0.19
AS2674723 0.03 3.7 ± 0.5 2.3 ± 0.3 0.63 0.1 2.3 ± 0.5 1.8 ± 0.5 0.80
Plasma (ng/mL) and brain (ng/g wet weight) concentrations of each compoundweremeasured at 1 h after oral administration of compounds inmice and aged rats. All data are
shown as mean ± SEM. n ¼ 3 for each point.
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Fig. 2. Effects of ASP5736 (A and B), AS2030680 (C and D) and AS2674723 (E and F) on working memory deﬁcits caused by scopolamine in the mouse Y-maze test. Data are
alternation rate (A, C and E) and total number of arm entries (B, D and F). Each value shows the mean ± SEM. n ¼ 8 for each group. Dotted line indicates chance level. #P < 0.05,
##P < 0.01, statistically signiﬁcant compared with control (vehicle þ saline-treated) group (Student's t-test). *P < 0.05, **P < 0.01, statistically signiﬁcant compared to vehicle-treated
scopolamine group (Dunnett's multiple comparison test).
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Fig. 3. Effects of ASP5736 (A and B), AS2030680 (C and D) and AS2674723 (E and F) on performance of aged rats in Morris water maze. Data are mean daily latencies to ﬁnd the
hidden platform (A, C and E) and cumulative latency for four days (B, D and F). Animals were subjected to 2 trials per day for 4 consecutive days. Values are mean ± SEM. n ¼ 12 for
each group. ##P < 0.01, statistically signiﬁcant compared to vehicle-treated young rats (Student's t-test). *P < 0.05, **P < 0.01, statistically signiﬁcant compared to vehicle-treated
aged rats (Dunnett's multiple comparison test).
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These ﬁndings might explain the lack of dose-dependency in our
behavioral studies.
We also conﬁrmed the efﬁcacy of the 5-HT5A antagonist for the
native 5-HT5A receptor in ex vivo brain slices from rats. While the 5-
HT5A receptor is also expressed in CNS areas other than olfactory
bulb, other 5-HT receptor subtypes for which LSD has afﬁnity dis-
played lower expression in this area. Further, Grailhe et al. (4) re-
ported that comparative autoradiography studies of the brains of
wild-type and 5-HT5A knockout mice revealed the presence of
binding sites with a high afﬁnity for [125I]-LSD that correspond to
the 5-HT5A receptors and are concentrated in the olfactory bulb,
neocortex, andmedial habenula. The occupancy rate of ASP5736 for
5-HT5A receptors in the olfactory bulb of rats was therefore evalu-
ated using [125I]-LSD in the presence of spiperone and clozapine.
ASP5736 exhibited dose-dependent receptor occupancy with anED50 value of 0.033 mg/kg, and ASP5736 bound to brain 5-HT5A
receptors (15%e50%) at doses effective for the relief of memory
deﬁcit of aged rats in a water maze task.
Here, we evaluated the effects of the potent 5-HT5A receptor
antagonists, ASP5736, AS2030680 and AS2674723 on cognitive
function. All three compounds had a high afﬁnity for 5-HT5A re-
ceptors of various species. Although each compound exhibited an
afﬁnity for other receptors, such as the 5-HT7 receptor and a2-
adrenergic receptor, 5-HT5A was the only receptor for which they
all exhibited a high afﬁnity. Each of the three compounds amelio-
rated scopolamine-induced working memory impairment in mice
in the Y-maze and improved reference memory deﬁcit in aged rats
in the Morris water maze. Further, ASP5736 exhibited dose-
dependent receptor occupancy with an ED50 value of 0.033 mg/
kg, and bound to brain 5-HT5A receptors at doses effective in
relieving memory deﬁcit of aged rats in a water maze task. These
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Fig. 4. 5-HT5A receptor occupancy of ASP5736 in rat olfactory bulb. Results expressed
as mean percentage of receptor occupancy vs. vehicle-treated rats ± SEM. n ¼ 4e5 for
each group.
M. Yamazaki et al. / Journal of Pharmacological Sciences 127 (2015) 362e369 369results indicate that the 5-HT5A receptor is involved in learning and
memory and, consistent with our previous report (7), suggest that
5-HT5A receptor antagonists might effectively treat cognitive
impairment associated with schizophrenia and dementia (mild
cognitive impairment).
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